Submitting OIG:
Report Description:
When Congress established average sales prices (ASPs) as the basis for Medicare Part B drug reimbursement, it also provided a mechanism for monitoring market prices and limiting potentially excessive payment amounts. Generally, Part B-covered drugs are those that are injected or infused in physicians' offices or hospital outpatient settings. The Social Security Act (the Act) mandates that OIG compare ASPs with average manufacturer prices (AMPs). If OIG finds that the ASP for a drug exceeds the AMP by a certain percentage (currently 5 percent), the Act directs the Secretary of Health and Human Services to substitute the ASPbased payment amount with a lower calculated rate. Through regulation, CMS outlined that it would make this substitution only if the ASP for a drug exceeds the AMP by 5 percent in the two previous quarters or three of the previous four quarters.
Date Issued:
Wednesday, August 12, 2020
Agency Reviewed / Investigated:
Submitting OIG-Specific Report Number:
OEI-03-20-00130
Location(s):
Agency-Wide
Type of Report:
Inspection / Evaluation
View Document:
Attachment | Size |
---|---|
OEI-03-20-00130.pdf | 1.07 MB |
Additional Details Link: